Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald Trump’s recent actions and his effect on the stock market, urging investors to pay closer attention to his moves.

“Look, people on Wall Street, you better start taking the President of the United States more seriously or else you’re gonna keep losing money. Look, you don’t have to like him, but I’m begging you, listen to his words.”

READ ALSO 12 Stocks on Jim Cramer’s Radar and Jim Cramer On 9 Stocks That Are Rallying Despite Tariff Worries

Cramer pointed to last Friday, when President Trump announced significant tariffs on Canada and Mexico, 25% while only imposing a 10% tariff on China. The decision left many on Wall Street shaken, especially since Trump’s actions have been anything but superficial. Cramer explained that the president’s moves are not idle threats.

“Of course, it’s not just tariffs. Yesterday the president said we’re gonna have a sovereign wealth fund like the Saudis. I heard a lot of snickering about that one, a lot of disparagement, a lot of laughs. “

He questioned why Wall Street seemed to dismiss the idea outright. He pointed out that, despite widespread criticism of many of Trump’s cabinet choices, Senate Republicans have consistently backed him. “They’re scared to death of the guy,” Cramer observed. According to Cramer, whether or not one likes Trump is irrelevant, the fact remains that Congress and the courts are unlikely to stop him, except in cases where his actions are blatantly unconstitutional. Therefore, he argued, the creation of a sovereign wealth fund is likely to be successful.

“Now, I know that the president said on Friday that he doesn’t care what the stock market says about his tariffs, but that’s not because he’s oblivious to the market like his predecessor was. It’s because the sellers don’t get the plan. They’re the oblivious ones. They don’t get that he’s trying to do something that will ultimately end up being really good for the stock market and that’s how the stock market could rally today. That’s how it could recover yesterday.”

Our Methodology

For this article, we compiled a list of 8 stocks that were discussed by Jim Cramer during the episode of Mad Money aired on February 4. We listed the stocks in ascending order of their hedge fund sentiment as of the third quarter, which was taken from Insider Monkey’s database of 900 hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Jim Cramer Shed Light on These 8 Stocks Recently

8. Tempus AI, Inc. (NASDAQ:TEM)

Number of Hedge Fund Holders: 7

When a caller asked Cramer about Tempus AI, Inc. (NASDAQ:TEM), he suggested Stryker instead.

“Really wanna start with Tempus? I would start with Stryker. Let’s, let’s go a little higher end. I think Stryker’s the better one and if you want AI then you can go with Medtronic. Both are better than the one you picked. No offense to yours, but I like mine more.”

Tempus AI (NASDAQ:TEM) is a healthcare technology company that provides diagnostic testing, molecular profiling, and analytical services, along with platforms for clinical trial matching, research, and data analysis to healthcare providers, and pharmaceutical, and biotechnology companies. Over the past year, Cramer’s recommended SYK stock saw over 14% growth while MDT stock was up only 4.8% and TEM gained more than 53% over the same period.

Baron Funds stated the following regarding Tempus AI, Inc (NASDAQ:TEM) in its Q3 2024 investor letter:

“Shares of Tempus AI, Inc (NASDAQ:TEM) contributed to performance. Tempus is a cancer diagnostics company that provides genomic testing results. Tempus has also amassed an over 200 petabyte proprietary multimodal dataset that combines clinical patient data with genomic testing data. In addition to using this data to empower more intelligent diagnostics for its own tests, Tempus also licenses this data to biopharmaceutical companies which use it to design smarter clinical trials and identify potential new drug targets. We think this proprietary dataset is unique with meaningful barriers to entry, and brings meaningful value to biopharmaceutical R&D. As we mentioned in the letter from last quarter, shares have been incredibly volatile. We took advantage of this volatility to buy a meaningful position when shares sold off into the low $20’s per share from an IPO price of $37. When shares spiked into the mid-$70’s (likely due to short sellers covering losses as shares rose), we took profits on a meaningful portion of the investment as we believed valuation had become stretched (shares now trade in the high $40’s to low $50’s level). We like our position sizing now, and would add to the position at lower valuations. We believe that Tempus has significant growth ahead of it and we are excited about its unique business model.”

7. Cerence Inc. (NASDAQ:CRNC)

Number of Hedge Fund Holders: 10

Cramer was bullish on Cerence Inc. (NASDAQ:CRNC) and highlighted the big change in its stock price.

“Now, Cerence actually has some game. They had that good partnership. Let’s go with Cerence. You know why? I’ll tell you why. Because it’s down huge from $27 down to $12. I think you got a real interesting level. Let’s pull the trigger.”

Cerence (NASDAQ:CRNC) offers AI-driven virtual assistants and conversational AI solutions, including speech recognition, natural language understanding, and text-to-speech, along with edge software, cloud-connected components, and professional services for the mobility and transportation sector. As mentioned in our article, Jim Cramer Discussed These 29 Stocks Ahead Of Major AI Event, Cramer discussed the company during Squawk on the Street and stated:

“I’ve got Cerence. Now this is in honor of a tie up with, yes with NVIDIA. This is a company that’s run by Brian Krzanich, before that CDK and then of course the CEO of Intel. During a period where I still think Intel had some greatness… But I think the key thing about Cerence is that we have AI and there isn’t any limit to where it is. Hence AI is a multiple enhancer… I have Brian Krzanich on tonight. Now he’s Cerence, and of course that’s what we’re gonna talk about. Because of a deal with of course NVIDIA. But he knows the auto business. Cerence is auto, uh, AI, and I want to ask him what the hell happened. Because at the previous job he had was CDK software which was bought up by Brookfield in a leveraged buyout. This man knows about cars. He knows about semis. Something’s going on that makes it so cars are too expensive to repair. And it’s really hurting the working person.”